What is PT-141?
PT-141 (generic name: bremelanotide) is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH). Unlike traditional sexual dysfunction treatments that work peripherally (e.g., PDE5 inhibitors like sildenafil), PT-141 acts centrally — directly stimulating melanocortin receptors in the brain that are involved in sexual arousal.
The compound was originally derived from Melanotan II, another melanocortin peptide, when researchers observed unexpected sexual arousal as a side effect in early clinical testing.
How PT-141 Works
PT-141 is a melanocortin receptor agonist, primarily activating:
- MC3R and MC4R receptors in the central nervous system (hypothalamus and limbic regions)
- These receptors are involved in regulating sexual arousal, appetite, and energy homeostasis
- Unlike PDE5 inhibitors, it does not require sexual stimulation to work — it increases the intrinsic desire for sexual activity
FDA Approval & Indications
Vyleesi (bremelanotide) received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection into the abdomen or thigh at least 45 minutes before anticipated sexual activity.
HSDD is characterized by persistent low sexual desire that causes personal distress.
Research in Men
While not FDA-approved for men, PT-141 has been studied for:
- Erectile dysfunction, including in men who don’t respond to PDE5 inhibitors
- Enhancement of sexual arousal in healthy male volunteers
Results have been promising but no regulatory approval exists for these indications.
Side Effects
- Nausea (most common, often transient)
- Flushing (face, neck, chest)
- Transient blood pressure increase — blood pressure typically rises 6–12 mmHg and returns to baseline within 12 hours
- Headache
- Injection site bruising
Important Cautions
- Cardiovascular risk: The transient blood pressure elevation makes PT-141 contraindicated in patients with cardiovascular or cerebrovascular disease, or those taking antihypertensives
- Not for daily use
- Not to be used more than once per 24-hour period
- No more than 1 dose per 8 episodes per month (per FDA labeling)
Medical Disclaimer: PT-141/bremelanotide is a prescription medication. Off-label use should only occur under medical supervision. This content is for educational purposes only.
Related Reading
- PT-141 (Bremelanotide): A Complete Guide — Comprehensive review of PT-141’s FDA approval, RECONNECT trial data, and clinical use
- Peptide Therapy and Women’s Health — HSDD, PT-141 cardiovascular monitoring, and women’s sexual health peptides
- Peptide Drug Interactions and Safety Guide — Antihypertensive contraindications and BP monitoring protocols
- Peptide Safety: What to Know Before Starting — Risk assessment framework for any peptide protocol
Safety Profile Summary
FDA-approved safety profile for women with HSDD. Common side effects include nausea, flushing, and temporary blood pressure changes. Contraindicated in patients with cardiovascular disease.
References & Further Reading
- 1. Clayton AH, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health (Lond). 2016;12(3):325-37. [PubMed ↗]
- 2. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. [PubMed ↗]
- 3. FDA Drug Approval — Vyleesi (bremelanotide) for HSDD. U.S. Food & Drug Administration. 2019. [FDA ↗]
- 4. Diamond LE, et al. Double-Blind, Placebo-Controlled Evaluation of the Safety, Pharmacokinetic Properties and Pharmacodynamic Effects of Intranasal PT-141. Int J Impot Res. 2004;16(1):51-9. [PubMed ↗]